Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Exelixis Inc (EXEL)  
$42.65 0.06 (0.14%) as of 4:30 Wed 2/4


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 310,240,000
Market Cap: 13.23(B)
Last Volume: 2,608,857 Avg Vol: 2,443,421
52 Week Range: $32.8 - $46.61
Level I Sector: Industrials
Level II Sector: Diversified Services
Level III Sector: Research Services

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 11.8
Insider 6 Months    : 11.8
Insider 3/6 Months : 24
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 27,532 27,532 27,532 642,532
Total Buy Value $1,187,235 $1,187,235 $1,187,235 $13,853,924
Total People Bought 1 1 1 1
Total Buy Transactions 1 1 1 4
Total Shares Sold 245,235 245,235 1,007,274 1,879,706
Total Sell Value $10,490,620 $10,490,620 $42,655,760 $67,526,158
Total People Sold 4 4 14 15
Total Sell Transactions 6 6 30 54
End Date 2025-11-06 2025-08-05 2025-02-04 2024-02-05

   
Records found: 1121
  Page 1 of 45  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Haley Patrick J. EVP, Commercial   •       –      –    2026-01-15 4 D $45.23 $1,462,376 D/D (32,332) 481,205     -
   Haley Patrick J. EVP, Commercial   •       –      –    2026-01-15 4 A $0.00 $0 D/D 139,508 513,537     -
   Aftab Dana EVP, Research and Development   •       –      –    2026-01-15 4 D $45.23 $1,232,698 D/D (27,254) 733,102     -
   Aftab Dana EVP, Research and Development   •       –      –    2026-01-15 4 A $0.00 $0 D/D 119,578 760,356     -
   Senner Christopher J. EVP and CFO   •       –      –    2026-01-15 4 D $45.23 $1,829,961 D/D (40,459) 1,076,857     -
   Senner Christopher J. EVP and CFO   •       –      –    2026-01-15 4 A $0.00 $0 D/D 149,474 1,117,316     -
   Morrissey Michael M President and CEO   •       •      –    2026-01-15 4 D $45.23 $6,310,671 D/D (139,524) 1,825,241     -
   Morrissey Michael M President and CEO   •       •      –    2026-01-15 4 A $0.00 $0 D/D 548,073 1,964,765     -
   Caligan Partners Lp See Remarks   –       •      –    2025-11-25 4 B $43.12 $1,187,235 I/I 27,532 1,553,262 2.1 -1%     
   Haley Patrick J. EVP, Commercial   •       –      –    2025-11-21 4 S $42.58 $1,194,071 D/D (28,043) 374,029 -0%     
   Aftab Dana EVP, Research and Development   •       –      –    2025-11-21 4 GD $0.00 $0 D/D 24,000 640,778     -
   Haley Patrick J. EVP, Commercial   •       –      –    2025-11-20 4 S $41.77 $1,431,757 I/I (34,187) 0 -2%     
   Haley Patrick J. EVP, Commercial   •       –      –    2025-11-20 4 S $42.11 $421,100 D/D (10,000) 402,072 -2%     
   Oliver Bob Director   –       •      –    2025-11-17 4 GD $0.00 $0 D/D 1,044 42,282     -
   Morrissey Michael M President and CEO   •       •      –    2025-11-12 4 GD $0.00 $0 I/I 80,000 1,714,404     -
   Morrissey Michael M President and CEO   •       •      –    2025-11-12 4 GA $0.00 $0 I/I 101,548 1,794,404     -
   Morrissey Michael M President and CEO   •       •      –    2025-11-12 4 GD $0.00 $0 D/D 101,548 1,416,692     -
   Papadopoulos Stelios Director   –       •      –    2025-11-12 4 S $43.55 $4,355,000 D/D (100,000) 1,189,228 2%     
   Aftab Dana EVP, Research and Development   •       –      –    2025-11-11 4 S $42.50 $2,056,278 D/D (48,383) 664,778 1%     
   Morrissey Michael M President and CEO   •       •      –    2025-11-11 4 GD $0.00 $0 I/I 160,000 1,692,856     -
   Beckerle Mary C Director   –       •      –    2025-11-11 4 S $41.90 $1,032,414 D/D (24,622) 21,380 1%     
   Beckerle Mary C Director   –       •      –    2025-11-11 4 OE $23.24 $134,420 D/D 5,784 46,002     -
   Hefti Brenda SVP and General Counsel   •       –      –    2025-11-07 3 IO $0.00 $0 I/I 0 5,527 4%     
   Hefti Brenda SVP and General Counsel   •       –      –    2025-11-07 3 IO $0.00 $0 D/D 0 90,441 4%     
   Aftab Dana EVP, Research & Development   •       –      –    2025-10-08 4 A $0.00 $0 D/D 50,673 713,161     -
  1121 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 45
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2026 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us